drugset / Trial / NCT04880811
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 trial investigating the effect and safety of afatinib plus toripalimab in previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR amplification.
Timeline
- Start
- 2021-07
- Primary completion
- 2022-10
- Completion
- 2023-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 40 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 200 mg | Intravenous |